Drug Search Results
More Filters [+]

Icodextrin

Alternative Names: icodextrin, extraneal
Latest Update: 2024-07-09
Latest Update Note: Clinical Trial Update

Product Description

Icodextrin (Extraneal) is a high molecular weight glucose polymer developed specifically for use as an alternative osmotic agent to dextrose during the once-daily long-dwell exchange in peritoneal dialysis (PD) (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12962523/)

Mechanisms of Action: ADRA2A Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | United States | Uruguay | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Baxter Healthcare
Company Location: DEERFIELD IL 60015
Company CEO: José E. Almeida
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Icodextrin

Countries in Clinic: Mexico

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Heart Failure

Phase 1: Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PURE

P2

Active, not recruiting

Heart Failure

2024-11-16

R-2022-785-034

P1

Recruiting

Kidney Failure, Chronic

2023-08-30

Recent News Events